Looking to make donor cells obsolete, an ex-Harvard researcher gets off-the-shelf stem cell biotech off the ground
A stem cell researcher who spent time at the Harvard Stem Cell Institute, the Broad Institute and Brigham and Women’s Hospital launched a new biotech Thursday, and he’s attracted significant blue-chip investment to get things up and running.
Dhvanit Shah unveiled a $72 million Series A for Garuda Therapeutics with the goal of developing off-the-shelf blood stem cell therapies. Shah, who founded Garuda and serves as CEO, told Endpoints News that while he recognizes other companies are researching off-the-shelf cell therapies, Garuda differentiates itself by trying to eliminate the need for donor cells entirely.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.